Poor
Not Aligned
Patient Risk:
High
Summary
Claims regarding FDA pregnancy Category D and specific animal findings and causal attribution in a human case are not supported by the provided FDA label excerpts; the label excerpt only states embryo-fetal toxicity based on animal data and mechanism of action, without Category D classification details or the specific malformation/embryolethality descriptions.
Category Scores
Accurate Statements
ZEPZELCA can cause fetal harm when administered to a pregnant woman.
Supported by SECTION 5.5 Embryo-Fetal Toxicity and SECTION 8.1 Pregnancy: “ZEPZELCA can cause fetal harm when administered to a pregnant woman.”
Unsupported Statements
Lurbinectedin is a Category D medication according to the FDA.
The provided label excerpts do not include any pregnancy category (e.g., Category D).
FDA Category D classification indicates evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans.
The pregnancy category framework/definition is not present in the provided label excerpts.
Potential benefits of lurbinectedin may warrant use in pregnant women despite potential risks.
The provided label excerpts do not state a recommendation that benefits may warrant use despite potential risks.
In animal studies in pregnant rats, lurbinectedin caused embryolethality.
No species-specific findings (rats; embryolethality) are described in the provided label excerpts.
In animal studies in pregnant rats, lurbinectedin caused fetal malformations.
No species-specific findings (rats; fetal malformations) are described in the provided label excerpts.
In animal studies in pregnant rats, lurbinectedin is teratogenic and embryotoxic.
The provided label excerpts state “Based on animal data… ZEPZELCA can cause fetal harm” but do not use or specify the terms teratogenic/embryotoxic or describe those specific outcomes.
In animal studies in pregnant rabbits, lurbinectedin caused embryolethality.
No species-specific findings (rabbits; embryolethality) are described in the provided label excerpts.
In animal studies in pregnant rabbits, lurbinectedin caused fetal malformations.
No species-specific findings (rabbits; fetal malformations) are described in the provided label excerpts.
In animal studies in pregnant rabbits, lurbinectedin is teratogenic and embryotoxic.
The provided label excerpts do not specify those species or that terminology.
A human case report described congenital heart defect in a baby exposed to lurbinectedin in utero during the first trimester of pregnancy.
The provided label excerpts do not mention any human case reports or specific congenital heart defect outcomes.
The congenital heart defect in the reported human case was attributed to lurbinectedin exposure.
Attribution language based on a specific case is not present in the provided label excerpts.
Contradictions
Important Omissions
When discussing pregnancy, the label excerpts also include advising women not to breastfeed during treatment and for 2 weeks after the last dose, and contraception for 7 months after the last dose.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Unsupported pregnancy-category claims and specific outcome/attribution assertions (animal species outcomes and a human case) could mislead risk characterization beyond what is supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple pregnancy-related assertions (FDA Category D classification, specific rat/rabbit embryolethality and malformations, and a human case with attributed congenital heart defect) are not supported by the provided prescribing information excerpts.
Suggested Improvement
Limit pregnancy statements to what the excerpts support (i.e., ZEPZELCA can cause fetal harm based on animal data/mechanism of action, and include the label-supported counseling points about breastfeeding and contraception). Remove pregnancy Category D references and any species-specific or case-report attribution details that are not present in the provided label excerpts.